Barclays raised the firm’s price target on Alphatec (ATEC) to $22 from $21 and keeps an Overweight rating on the shares. The company reported a Q2 “beat and raise” on 29% surgical growth and has “plenty of runway” for further growth, the analyst tells investors in a research note. The firm views the stock as attractive at current levels.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ATEC:
- Alphatec’s Financial Health at Risk Amid Potential U.S. Trade Policy Changes
- Alphatec’s Earnings Call Highlights Robust Growth and Future Prospects
- Alphatec Holdings: Strong Financial Performance and Growth Prospects Justify Buy Rating
- Alphatec Holdings: Strong Performance and Promising Outlook Justify Buy Rating
- Alphatec Holdings Reports Strong Q2 2025 Results